ADA Scientific Sessions 2025 Abstract

Hospitalization Is a Risk Factor for SGLT2i Discontinuation

By Tamara Y. Milder, Leah Shepherd, Sallie-Anne Pearson, Michael O. Falster

Study in peoplePopulations

The paper

Tamara Y. Milder, Leah Shepherd, Sallie-Anne Pearson, Michael O. Falster

Copenhagen NV

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 904-P

doi.org/10.2337/db25-904-p

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes